Regcell raised $66 million in new financing along with Japanese government support to move its Nobel-linked regulatory T-cell platform toward the clinic. The company’s approach centers on epigenetic reprogramming intended to convert disease-driving immune cells into antigen-specific Tregs. The funding provides runway as Regcell advances preclinical work into human studies, reflecting continued investor interest in immune tolerance technologies that aim to address autoimmune drivers without broad immunosuppression. For the field, the emphasis on antigen-specificity highlights where Treg engineering is targeting higher precision and potentially better durability of response.